GlobeNewswire: DSS, Inc. Contains the last 10 of 175 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T00:33:27ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/01/30/2819971/0/en/Impact-Biomedical-Inc-Announces-U-S-Patent-Allowance-of-Laetose-Technology-Entitled-Low-Glycemic-Sugar-Composition.html?f=22&fvtc=4&fvtv=43332Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition."2024-01-30T13:05:56Z<![CDATA[NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose™ technology platform. The U.S. Patent and Trademark Office (USPTO) has issued U.S. patent # 11,898,184, entitled "Low Glycemic Sugar Composition" developed within this platform.]]>https://www.globenewswire.com/news-release/2024/01/04/2803989/0/en/DSS-Inc-Chairman-Chan-Acquires-672-173-shares-of-DSS-In-Open-Market.html?f=22&fvtc=4&fvtv=43332DSS, Inc. Chairman Chan Acquires 672,173 shares of DSS In Open Market2024-01-04T13:15:00Z<![CDATA[Chairman of the Board Heng Fai Ambrose Chan Adds 672,173 Shares to Increase Investment in Company Chairman of the Board Heng Fai Ambrose Chan Adds 672,173 Shares to Increase Investment in Company]]>https://www.globenewswire.com/news-release/2023/12/22/2800840/0/en/DSS-Inc-Announces-Reverse-Split-as-Part-of-NYSE-American-Compliance-Plan.html?f=22&fvtc=4&fvtv=43332DSS, Inc. Announces Reverse Split as Part of NYSE American Compliance Plan2023-12-22T21:30:00Z<![CDATA[NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS, “Company”), a multinational company operating nine (9) diversified business lines developed through strategic acquisitions to build shareholder value through periodic spinoffs to its shareholders, today announced that it will proceed with a 1-for-20 reverse stock split (the “Reverse Split”) of its issued and outstanding shares of common stock, par value $0.02, following authorization by its Board of Directors and majority shareholders to effect a reverse split by a ratio of not less than 1-for-20 and not more than 1-for-40 (the “Reverse Split Range”), at any time on or before April 20, 2024, with the Board having the discretion as to whether or not the Reverse Split is to be effected, and with the exact ratio to be set at a whole number within the Reverse Split Range as determined by the Chief Executive Officer in his discretion.]]>https://www.globenewswire.com/news-release/2023/11/28/2786916/0/en/Premier-Packaging-a-Wholly-Owned-Subsidiary-of-DSS-Inc-Secures-Contract-Extension-with-Major-Retailer-Worth-Up-to-15-Million-over-Four-Years.html?f=22&fvtc=4&fvtv=43332Premier Packaging, a Wholly-Owned Subsidiary of DSS, Inc., Secures Contract Extension with Major Retailer Worth Up to $15 Million over Four Years2023-11-28T13:10:00Z<![CDATA[Option for Fourth Year Brings Potential Revenue to Over $15 Million Option for Fourth Year Brings Potential Revenue to Over $15 Million]]>https://www.globenewswire.com/news-release/2023/11/14/2780031/0/en/DSS-Inc-Wins-Patent-Dispute-with-Nichia-Corporation.html?f=22&fvtc=4&fvtv=43332DSS Inc. Wins Patent Dispute with Nichia Corporation2023-11-14T13:00:00Z<![CDATA[NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) announced today that, in a unanimous decision, the Court of Appeals for the Federal Circuit (CAFC) rejected Nichia Corp.'s challenge to U.S. Patent No. 6,879,040 (the ‘040 Patent). U.S. Chief Circuit Judge Kimberly Moore, who authored the opinion, and U.S. Circuit Judges Kara Stoll and Tiffany Cunningham sat on the panel for the Federal Circuit.]]>https://www.globenewswire.com/news-release/2023/11/08/2776270/0/en/DSS-Inc-Subsidiary-Files-Current-Report-on-Form-8-K-Disclosing-Reverse-Split-of-Outstanding-and-Issued-Common-Stock-and-Conversion-of-Certain-Holder-s-Common-Stock.html?f=22&fvtc=4&fvtv=43332DSS, Inc. Subsidiary Files Current Report on Form 8-K Disclosing Reverse Split of Outstanding and Issued Common Stock and Conversion of Certain Holder’s Common Stock2023-11-08T13:31:00Z<![CDATA[DSS Shareholders to Benefit from Reduction in Common Stock of Impact Biomedical DSS Shareholders to Benefit from Reduction in Common Stock of Impact Biomedical]]>https://www.globenewswire.com/news-release/2023/10/26/2768072/0/en/DSS-Inc-Receives-Notice-of-Non-Compliance-with-NYSE-American-Trading-Share-Price-Listing-Rule.html?f=22&fvtc=4&fvtv=43332DSS Inc. Receives Notice of Non-Compliance with NYSE American Trading Share Price Listing Rule2023-10-26T21:25:00Z<![CDATA[Company intends to cure the deficiency and return to compliance with NYSE American standard Company intends to cure the deficiency and return to compliance with NYSE American standard]]>https://www.globenewswire.com/news-release/2023/10/23/2764710/0/en/DSS-Inc-Announces-Filing-of-Registration-Statement-on-Form-S-1-for-Initial-Public-Offering-of-Impact-Biomedical.html?f=22&fvtc=4&fvtv=43332DSS, Inc. Announces Filing of Registration Statement on Form S-1 for Initial Public Offering of Impact Biomedical2023-10-23T12:25:00Z<![CDATA[NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- DSS, Inc.(NYSE American: DSS) ("DSS") announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of the Company's wholly-owned subsidiary, Impact Biomedical (hyperlink: https://www.impactbiomedinc.com/). DSS, Inc. intends to list Impact Biomedical on the NYSE American exchange. The number of shares of Class A common stock to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market conditions.]]>https://www.globenewswire.com/news-release/2023/10/12/2759232/0/en/DSS-Inc-Issues-Letter-to-Shareholders.html?f=22&fvtc=4&fvtv=43332DSS Inc. Issues Letter to Shareholders2023-10-12T12:25:00Z<![CDATA[CEO Highlights Expected IPO of Impact Biomedical and Progress in Subsidiaries CEO Highlights Expected IPO of Impact Biomedical and Progress in Subsidiaries]]>https://www.globenewswire.com/news-release/2023/09/06/2738430/0/en/DSS-Inc-Expands-DSS-Wealth-Management-Inc-s-Management-Team-for-Ramp-Up-of-Asset-Management-Subsidiary.html?f=22&fvtc=4&fvtv=43332DSS Inc. Expands DSS Wealth Management, Inc.'s Management Team for Ramp Up of Asset Management Subsidiary2023-09-06T12:40:00Z<![CDATA[Jim Monaghan Appointed Chief Operating Officer and Chief Compliance Officer; Michael Cheah Joins as Portfolio Manager and Head of Fixed Income Jim Monaghan Appointed Chief Operating Officer and Chief Compliance Officer; Michael Cheah Joins as Portfolio Manager and Head of Fixed Income]]>